1.	Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LAP-R2007, NCT00504764
2.	Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
3.	Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: MYFLAI07, NCT00909168
4.	Phase III Randomized Study of Conventional Combination Chemotherapy With Versus Without Gemtuzumab Ozogamicin in Young Patients With Newly Diagnosed Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: Under 30 Sponsor: NCI Protocol IDs: COG-AAML0531, AAML0531, NCT00372593
5.	Phase III Randomized Study of Induction and Consolidation Combination Chemotherapy With or Without Gemtuzumab Ozogamicin Followed By Maintenance Therapy Comprising Tretinoin, Mercaptopurine, and Methotrexate Versus Observation in Patients With Previously Untreated Low- or Intermediate-Risk Acute Promyelocytic Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0521, S0521, NCT00492856
6.	NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: NOPHO-AML 2004, NCT00476541
7.	Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: BRD 06/10-I, NCT00860639
8.	Study of Chemotherapy in Combination With All-Trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: AMLSG 09-09, NCT00893399
9.	A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old Phase: Phase III Type: Treatment Status: Active Age: 50 to 70 Sponsor: Other Protocol IDs: ALFA 0701, NCT00927498
10.	Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: EK 92062003, NCT00460447
11.	Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 07-154, NCT00660036
12.	A Trial of the Combination 5-Azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: 050938, NCT00766116
13.	Phase I/II Study of Vorinostat, Gemtuzumab Ozogamicin, and Azacitidine in Older Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 50 and over Sponsor: NCI Protocol IDs: FHCRC-2288.00, FHCRC-2288.00, 8297, IR-6921, NCT00895934
14.	All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab and Theophylline Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2006-0706, NCT00413166
15.	Phase II Study of Induction and Consolidation Therapy Comprising Tretinoin, Arsenic Trioxide, and Gemtuzumab Ozogamicin Followed by Maintenance Therapy Comprising Tretinoin, Mercaptopurine, and Methotrexate in Patients With Previously Untreated, High-Risk Acute Promyelocytic Leukemia Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0535, S0535, NCT00551460
16.	Phase II Study of Azacitidine and Gemtuzumab Ozogamicin as Induction and Post-Remission Therapy in Older Patients With Previously Untreated Acute Myeloid Leukemia Phase: Phase II Type: Treatment Status: Active Age: 60 and over Sponsor: NCI Protocol IDs: SWOG-S0703, S0703, NCT00658814
17.	Phase II Pilot Study of Induction and Post-Remission Therapy Comprising Vorinostat and Gemtuzumab Ozogamicin in Older Patients With Previously Untreated Acute Myeloid Leukemia Phase: Phase II Type: Treatment Status: Active Age: 60 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: FHCRC-2200.00, 6688, IR-6688, MERCK-FHCRC-2200.00, NCT00673153
18.	SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717) Phase: Phase II Type: Treatment Status: Active Age: 60 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P04717, NCT00798213
19.	Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin in CBF Leukemias Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-0147, NCT00801489
20.	Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: 2008-0288, NCT00882102
21.	Phase I Study of Clofarabine and Gemtuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase: Phase I Type: Treatment Status: Active Age: 18 to 60 Sponsor: NCI Protocol IDs: UNC-LCCC-0708, LCCC 0708, UNC-LCCC-07-1222, NCT00577694
22.	Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML Phase: Phase I Type: Treatment Status: Active Age: 30 and under Sponsor: Other Protocol IDs: CHNY-01-515, AAAA2533, NCT00669890